当前位置: 首页 > 期刊 > 《上海医药》 > 2022年第3期
编号:52302
参芪颗粒配合低剂量化疗肝动脉介入栓塞治疗中晚期肝癌的临床研究
http://www.100md.com 2022年3月5日 2022年第3期
     刘治辉

    摘 要 目的:探究参芪颗粒配合低剂量化疗肝动脉介入栓塞(TACE)治疗中晚期肝癌的临床疗效。方法:选取60例中晚期肝癌患者,用随机数字表法分为观察组(n=30)和对照组(n=30)。对照组给予常规剂量TACE治疗,观察组给予参芪颗粒配合低剂量化疗TACE治疗。比较两组的临床疗效和安全性。结果:治疗后,观察组的疾病控制率、中医症状改善率、甲胎蛋白有效率、白细胞计数水平等高于对照组(P<0.05),各不良反应发生率低于对照组(P<0.05)。结论:参芪颗粒配合低剂量化疗TACE治疗中晚期肝癌可改善肝功能,提高临床疗效,降低不良反应。

    关键词 肝癌 中晚期 化疗 肝动脉介入栓塞 参芪颗粒

    中图分类号:R286; R735.7 文献标志码:B 文章编号:1006-1533(2022)03-0042-04

    Clinical study of Shenqi granule combined with low-dose chemotherapy for hepatic artery interventional embolization in the treatment of advanced liver cancer

    LIU Zhihui

    (Department of Oncology, Xuchang Municipal Hospital, Xuchang 461000, China)

    ABSTRACT Objective: To investigate the clinical efficacy of Shenqi granule combined with low-dose chemotherapy for hepatic transcatheter artery interventional chemoembolization (TACE) in the treatment of advanced hepatocellular carcinoma. Methods: Sixty patients with advanced liver cancer were selected and randomly divided into an observation group (n=30) and a control group (n=30). The control group was treated with conventional doses of TACE while the observation group with Shenqi granules combined with low-dose chemotherapy TACE. The clinical efficacy and safety were compared between the two groups. Results: After the treatment ......

您现在查看是摘要页,全文长 10414 字符